Loading data for TYRA — first visit, this takes a few seconds.

Tyra Biosciences, Inc. (TYRA)

NasdaqGS: TYRA · 即時價格 · USD

28.65

+3.79 (15.25%)

收盤價： Sep 04, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	21.1
市值	1.71B
營收 (ttm)	n/a
淨利（ttm）	-149M
	0.73
	-2.39
	n/a
	-9.67
P/B (ttm)	4.83
P/S (ttm)	0.00
財報日期	Nov 4, 2026

賣價	31.8
成交量	1,864,290
20 日平均成交量	734,203
開盤價	24.51
前收盤價	24.86
當日區間	24.51 - 29.55
52 週範圍	11.70 - 40.65
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 TYRA

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clin...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Sep 15, 2021

員工 87

證券交易所 NasdaqGS

股票代號 TYRA

網站 https://tyra.bio

完整的公司簡介

財務表現

Tyra Biosciences 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -119.95M，較前期增加 38.7%。

財務報表

財報驚奇

Tyra Biosciences 已於 Aug 4, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.69 低於預期 -0.05, 年增 -46.81% 下滑.

下次財報發布

Tyra Biosciences, Inc. 的下次財報預計於 Nov 4, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 天前 · Stocktwits

TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout

Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.

2 月前 · Insider Monkey

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly repor...

2 月前 · Simply Wall St.

Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

Recently, analysts issued mixed commentary on Tyra Biosciences, balancing optimism around its FGFR3 inhibitor dabogratinib and a new board appointment with renewed questions about the SURF-302 program...

2 月前 · MT Newswires

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

Tyra Biosciences' (TYRA) weak investor sentiment reflects a mix of macro pressures, profit-taking, a

3 月前 · Insider Monkey

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Pe...

第 1 頁，共 2 頁

Tyra Biosciences, Inc. (TYRA)